|
1
|
Gerotziafas GT, Taher A, Abdel-Razeq H,
AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK and Elalamy
I: COMPASS-CAT Working Group. A predictive score for thrombosis
associated with breast, colorectal, lung, or ovarian cancer: The
prospective compass-cancer-associated thrombosis study. Oncologist.
22:1222–1231. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chandra A, Pius C, Nabeel M, Nair M,
Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status
and strategies for improving therapeutic outcomes. Cancer Med.
8:7018–7031. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Matsuura Y, Robertson G, Marsden DE, Kim
SN, Gebski V and Hacker NF: Thromboembolic complications in
patients with clear cell carcinoma of the ovary. Gynecol Oncol.
104:406–410. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang W, Liu X, Cheng H, Yang Z and Zhang
G: Risk factors and treatment of venous thromboembolism in
perioperative patients with ovarian cancer in China. Medicine
(Baltimore). 97(e11754)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Satoh T, Oki A, Uno K, Sakurai M, Ochi H,
Okada S, Minami R, Matsumoto K, Tanaka YO, Tsunoda H, et al: High
incidence of silent venous thromboembolism before treatment in
ovarian cancer. Br J Cancer. 97:1053–1057. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tasaka N, Minaguchi T, Hosokawa Y, Takao
W, Itagaki H, Nishida K, Akiyama A, Shikama A, Ochi H and Satoh T:
Prevalence of venous thromboembolism at pretreatment screening and
associated risk factors in 2086 patients with gynecological cancer.
J Obstet Gynaecol Res. 46:765–773. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kawaguchi R, Furukawa N and Kobayashi H:
Cut-off value of D-dimer for prediction of deep venous thrombosis
before treatment in ovarian cancer. J Gynecol Oncol. 23:98–102.
2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bakhru A: Effect of ovarian tumor
characteristics on venous thromboembolic risk. J Gynecol Oncol.
24:52–58. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tang N, Pan Y, Xu C and Li D:
Characteristics of emergency patients with markedly elevated
D-dimer levels. Sci Rep. 10(7784)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Beer JH, Haeberli A, Vogt A, Woodtli K,
Henkel E, Furrer T and Fey MF: Coagulation markers predict survival
in cancer patients. Thromb Haemost. 88:745–749. 2002.PubMed/NCBI
|
|
11
|
Shorr AF, Thomas SJ, Alkins SA,
Fitzpatrick TM and Ling GS: D-dimer correlates with proinflammatory
cytokine levels and outcomes in critically ill patients. Chest.
121:1262–1268. 2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Farolfi A, Petrone M, Scarpi E, Gallà V,
Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, et
al: Inflammatory indexes as prognostic and predictive factors in
ovarian cancer treated with chemotherapy alone or together with
bevacizumab. A multicenter, retrospective analysis by the MITO
group (MITO 24). Target Oncol. 13:469–479. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shi J, Huo R, Li N, Li H, Zhai T, Li H,
Shen B, Ye J, Fu R and Di W: CYR61, a potential biomarker of tumor
inflammatory response in epithelial ovarian cancer microenvironment
of tumor progress. BMC Cancer. 19(1140)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang Y, Zong X, Mitra S, Mitra AK, Matei D
and Nephew KP: IL-6 mediates platinum-induced enrichment of ovarian
cancer stem cells. JCI Insight. 3(e122360)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shim H, Lee YJ, Kim JH, Lim MC, Lee DE,
Park SY and Kong SY: Preoperative laboratory parameters associated
with deep vein thrombosis in patients with ovarian cancer:
Retrospective analysis of 3,147 patients in a single institute. J
Gynecol Oncol. 35(e38)2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wu J, Fu Z, Liu G, Xu P, Xu J and Jia X:
Clinical significance of plasma D-dimer in ovarian cancer: A
meta-analysis. Medicine (Baltimore). 96(e7062)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Takano M, Goto T, Kato M, Sasaki N,
Miyamoto M and Furuya K: Short response duration even in responders
to chemotherapy using conventional cytotoxic agents in recurrent or
refractory clear cell carcinomas of the ovary. Int J Clin Oncol.
18:556–557. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rauh-Hain JA, Melamed A, Wright A, Gockley
A, Clemmer JT, Schorge JO, Del Carmen MG and Keating NL: Overall
survival following neoadjuvant chemotherapy vs primary
cytoreductive surgery in women with epithelial ovarian cancer:
Analysis of the national cancer database. JAMA Oncol. 3:76–82.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Matsuo K, Hasegawa K, Yoshino K, Murakami
R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A,
et al: Venous thromboembolism, interleukin-6 and survival outcomes
in patients with advanced ovarian clear cell carcinoma. Eur J
Cancer. 51:1978–1988. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sakurai M, Matsumoto K, Gosho M, Sakata A,
Hosokawa Y, Tenjimbayashi Y, Katoh T, Shikama A, Komiya H,
Michikami H, et al: Expression of tissue factor in epithelial
ovarian carcinoma is involved in the development of venous
thromboembolism. Int J Gynecol Cancer. 27:37–43. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gunderson CC, Thomas ED, Slaughter KN,
Farrell R, Ding K, Farris RE, Lauer JK, Perry LJ, McMeekin DS and
Moore KN: The survival detriment of venous thromboembolism with
epithelial ovarian cancer. Gynecol Oncol. 134:73–77.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
23
|
Prat J: FIGO Committee on Gynecologic
Oncology. FIGO's staging classification for cancer of the ovary,
fallopian tube, and peritoneum: Abridged republication. J Gynecol
Oncol. 26:87–89. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
World Health Organization Classification
of Tumours Editorial Board: WHO classification of tumours 5th
edition female genital tumours. International Agency for Research
on Cancer, Lyon, pp34-167, 2020.
|
|
25
|
Kuplay H, Erdoğan SB, Bastopcu M,
Arslanhan G, Baykan DB and Orhan G: The neutrophil-lymphocyte ratio
and the platelet-lymphocyte ratio correlate with thrombus burden in
deep venous thrombosis. J Vasc Surg Venous Lymphat Disord.
8:360–364. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liang S, Tang W, Ye S, Xiang L, Wu X and
Yang H: Incidence and risk factors of preoperative venous
thromboembolism and pulmonary embolism in patients with ovarian
cancer. Thromb Res. 190:129–134. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Claussen C, Rausch AV, Lezius S,
Amirkhosravi A, Davila M, Francis JL, Hisada YM, Mackman N,
Bokemeyer C, Schmalfeldt B, et al: Microvesicle-associated tissue
factor procoagulant activity for the preoperative diagnosis of
ovarian cancer. Thromb Res. 141:39–48. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kerr R, Stirling D and Ludlam CA:
Interleukin 6 and haemostasis. Br J Haematol. 115:3–12.
2001.PubMed/NCBI View Article : Google Scholar
|
